January 11, 2022
Takeda Pharmaceutical’s proton pump inhibitor (PPI) Takecab (vonoprazan) was the top-selling drug in Japan in December, according to a monthly snapshot report released by Encise. Takecab retrieved the title from Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab), which topped the ranking...read more